Clinical trials: Patients With Type 2 Diabetes
Type 2 Diabetes Mellitus, Chronic Kidney Disease
A Study of Autologous Renal Autologous Cell Therapy (REACT) in Patients With Diabetic Chronic Kidney Disease
The purpose of the present study is to assess the safety and efficacy of up to 2 injections of REACT given 6 months (+4 weeks) apart (maximum).
- Trial name
- NCT03270956
- Testing
- Renal Autologous Cell Therapy (REACT)
- Where
- 4 sites in United States
- Volunteers
- 10 people
- Sponsor
- Prokidney
Type 2 Diabetes Mellitus
Pharmacokinetic/Pharmacodynamic Study of MP-513 With Type 2 Diabetes Mellitus
The purpose of this study is to evaluate the effect of MP-513 on 24-h glycemic control in patients with type 2 Diabetes for 4 weeks administration.
- Trial name
- NCT01072331
- Testing
- MP-513
- Where
- Japan
- Volunteers
- 99 people
- Sponsor
- Tanabe Pharma Corporation
Obese or Overweight Healthy Volunteers, Type 2 Diabetes Mellitus (T2DM)
A Study to Evaluate ALN-4324 in Overweight to Obese Healthy Volunteers and in Overweight to Obese Patients With T2DM
The purpose of this study is to: evaluate the safety and tolerability of single ascending doses of ALN-4324 in healthy volunteers and to characterize the single-dose PK of ALN-4324 evaluate the efficacy, safety, tolerability, PK…
- Trial name
- NCT06845202
- Testing
- ALN-4324
- Where
- 22 sites in United States, Argentina and 4 more
- Volunteers
- 105 people, healthy volunteers welcome
- Sponsor
- Alnylam Pharmaceuticals
Recent Onset type1 Diabetes
A Study of Oral Ladarixin in Recent Onset Type 1 Diabetes and a Low Residual β-cell Function
Objectives The objective of this clinical trial is to assess whether ladarixin treatment has an effect to preserve β-cell function and delay the progression of T1D in adolescent and adult patients.
- Trial name
- NCT04628481
- Testing
- Ladarixin
- Where
- 57 sites in United States, Belgium and 6 more
- Volunteers
- 289 people
- Sponsor
- Dompé Farmaceutici S.p.A
Type 2 Diabetes
Evaluation of Diabetes Care at Austrian GPs
This registery should show the medical care of patient with Type 2 Diabetes (T2D) at GP-offices. Furthermore data of co morbidities and risk factors should be evaluated.
- Trial name
- DCA09 (NCT00979394)
- Volunteers
- 1,513 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Japanese Phase 1 Multiple Ascending Dose Study
The purpose of this clinical study is to assess the safety and tolerability of multiple oral doses of BMS-823778 in healthy Japanese subjects and Japanese patients with Type 2 Diabetes Mellitus.
- Trial name
- NCT01515202
- Testing
- BMS-823778
- Where
- Japan
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Type 2 Diabetes Mellitus
A Study of the Co-administration of Sitagliptin and Atorvastatin in Inadequately Controlled Type 2 Diabetes Mellitus (MK-0431E-211)
This two-phase study was to examine if 16 weeks of treatment with sitagliptin in combination with atorvastatin reduces hemoglobin A1C (A1C) and low density lipoprotein cholesterol (LDL-C) from baseline more than atorvastatin…
- Trial name
- NCT01477853
- Testing
- Sitagliptin, Atorvastatin, Metformin (open-label)
- Volunteers
- 166 people
- Sponsor
- Merck Sharp & Dohme LLC
Renal Insufficiency, Chronic
Survey of Patient and Physician Awareness and Values to the Diagnosis and Treatment of Reduced Kidney Function (Chronic Kidney Disease) in Patients With High Blood Sugar Level (Type 2 Diabetes) (AWARE-CKD in T2D)
In this survey study, researchers want to find out more about how physicians are treating patients diagnosed with reduced kidney function (chronic kidney disease, CKD) and high blood sugar level (type 2 diabetes); what physicians…
- Trial name
- AWARE-CKD (NCT04498156)
- Testing
- No intervention
- Where
- Canada
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Bayer
Diabetes Mellitus, Type 2
A Clinical Trial Comparing Short-Term Efficacy and Safety of Exubera and Lantus
To compare short-term efficacy and safety of Exubera vs Lantus in patients with type 2 diabetes mellitus
- Trial name
- NCT00367445
- Testing
- Inhaled Human Insulin (Exubera), Insulin Glargine (Lantus)
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pfizer
Diabetes Mellitus, Type 2, Exocrine Pancreatic Insufficiency
A Study to Investigate How Common Pancreatic Exocrine Insufficiency (PEI) is in Patients With Type 2 Diabetes and Also to Investigate the Uptake of a Single Dose of EPANOVA® or OMACOR® in Patients With Different Degrees of PEI
This study is a 2-part open-label, randomized, crossover, multicenter, non-therapeutic Phase II study to investigate the presence of pancreatic exocrine insufficiency (PEI) in patients with Type 2 diabetes mellitus (T2DM), and to…
- Trial name
- PRECISE (NCT02370537)
- Testing
- Epanova® (omega-3 carboxylic acids), Omacor® (omega-3-acid ethyl esters)
- Where
- 22 sites in Denmark, Hungary and 4 more
- Volunteers
- 490 people
- Sponsor
- AstraZeneca
Type 2 Diabetes Mellitus
Type 2 Diabetes Patients Switched From Sulfonylurea With Metformin to Glyburide/Metformin Combination Tablet
To evaluate the efficacy and safety of type 2 diabetes patients switched from sulfonylurea co-administered with metformin to glyburide/metformin combination tablet.
- Trial name
- NCT00541437
- Where
- Taiwan
- Volunteers
- 12 people
- Sponsor
- Genovate Biotechnology Co., Ltd.,
Diabetes Mellitus, Type 2
A Research Study to Understand How People With Type 2 Diabetes Take Ozempic® and if the Ozempic®App Helps Them Stay on This Treatment
This study looks at how participants with type 2 diabetes take Ozempic® and if the Ozempic® app helps participants to stay on this treatment. Participants will already be prescribed with Ozempic® by the study doctor.
- Trial name
- NCT06478550
- Testing
- Semaglutide
- Where
- 6 sites in Greece
- Volunteers
- 304 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus Type 2
A Study of Taspoglutide Versus Pioglitazone in Patients With Type 2 Diabetes
This double-blind, double-dummy 3 arm study will evaluate the efficacy, safety and tolerability of taspoglutide versus pioglitazone in patients with type 2 diabetes mellitus inadequately controlled with sulfonylurea monotherapy…
- Trial name
- NCT00909597
- Testing
- pioglitazone, taspoglutide
- Where
- 147 sites in United States, Australia and 17 more
- Volunteers
- 756 people
- Sponsor
- Hoffmann-La Roche
Non-Insulin-Dependent Diabetes Mellitus
Study In Patients With Type 2 Diabetes Who Are Taking Metformin And Sulfonylurea, Metformin And Insulin, Or Insulin
This study will use Magnetic Resonance Imaging (MRI) techniques to evaluate changes in fluid volume in the lower legs of diabetic patients who add either pioglitazone or placebo to their current diabetic regimen.
- Trial name
- NCT00269061
- Testing
- pioglitazone
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- GlaxoSmithKline
Diabetes
Twelve -Month Study Observing How Insulin-naïve Patients With Type 2 Diabetes Mellitus Manage Diabetes Using Toujeo® After Oral Antidiabetic Drug Failure, the Side Effect of Toujeo®, and The Cost.
Primary Objective: Assess effectiveness of insulin glargine (U300) in achieving glycemic goal measured by hemoglobin A1c (HbA1c).
- Trial name
- ATOS (NCT03703869)
- Testing
- Insulin glargine (U300)
- Where
- 388 sites in Colombia, Egypt and 16 more
- Volunteers
- 4,589 people
- Sponsor
- Sanofi
Diabetes, Diabetes Mellitus, Type 2
Comparison of Insulin Detemir Morning, Insulin Detemir Evening and NPH Insulin Evening in Patients With Type 2 Diabetes
This trial is conducted in Europe and the United States of America (USA). The aim of this trial is to compare the use of Insulin Detemir once a day (morning or evening) to NPH Insulin once a day (evening) when added to treatment…
- Trial name
- NCT00104182
- Testing
- insulin detemir, insulin NPH
- Where
- 96 sites in United States, Denmark and 5 more
- Volunteers
- 503 people
- Sponsor
- Novo Nordisk A/S
Type 2 Diabetes
Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus
The purpose of this study is: To assess the efficacy of Nasulin vs. placebo as indicated by time spent in euglycemia, assessed by continuous glucose monitoring data and serum fructosamine levels in patient volunteers with Type 2…
- Trial name
- CPEX-011 (NCT00850096)
- Testing
- Nasulin
- Where
- 21 sites in United States
- Volunteers
- 94 people
- Sponsor
- CPEX Pharmaceuticals Inc.
Type 2 Diabetes Mellitus
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
The objective of this study is to evaluate efficacy and safety of initial combination therapy with Gemigliptin 50mg q.d and Metformin q.d compared with either monotherapy in treatment naïve patients with type 2 diabetes, In other…
- Trial name
- NCT01787396
- Testing
- Gemigliptin 50mg, Metformin
- Where
- South Korea
- Volunteers
- 433 people
- Sponsor
- LG Life Sciences
Pain, Chronic Pain
A Study of the Impact of Genetic Testing on Clinical Decision Making and Patient Care
The purpose of this study is to evaluate the impact of genetic testing on healthcare decisions and patient outcomes for patients suffering from pain, cardiovascular problems, Arthritis, Type II Diabetes, and/or Mental Health…
- Conditions
- Pain, Chronic Pain, Mental Disorders, Cardiovascular Diseases
- Trial name
- REVOLUTION (NCT02487888)
- Testing
- Unblinded to Genetic Testing Results, Blinded to Genetic Testing Results
- Where
- 31 sites in United States
- Volunteers
- 100,000 people
- Sponsor
- Proove Bioscience, Inc.
Essential Hypertension, Type 2 Diabetes Mellitus
Azilsartan Medoxomil in the Treatment of Essential Hypertension and Type 2 Diabetes in Asia
The purpose of this study is to evaluate the efficacy and safety of azilsartan medoxomil (AZM) in Asian adult participants with both essential hypertension and type 2 diabetes.
- Trial name
- NCT02517866
- Testing
- Azilsartan Medoxomil
- Where
- 11 sites in China, Taiwan and 1 more
- Volunteers
- 380 people
- Sponsor
- Takeda
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.